Abstract
Aim: The aim of this study was to replicate a previously reported association between drug resistance in epilepsy patients and the 24C>T variant of the ABCC2 gene that codes for the drug efflux transporter MRP2. Patients & methods: We genotyped 381 Caucasian epileptic patients (337 drug resistant and 44 drug responsive) and 247 healthy controls for the ABCC2 gene -24C>T polymorphism (rs717620) and two other nearby SNPs in linkage disequilibrium (1249G>A and 3972C>T). Genotype, allele and three-SNP-haplotype frequencies were compared between groups. Patients were further stratified into four groups according to their degree of drug resistance (as measured by seizure frequency under medication) to perform regression analysis against genotypes and haplotpyes. Results: We detected no significant differences in the distribution of any of the tested alleles, genotypes or haplotypes between the investigated groups. Neither was there an association between genotypes or haplotypes and degree of drug resistance. This study was adequately powered to detect genotype relative risks of above two. Conclusion: Although adequately powered to detect the previously reported effect size and although our definition of drug resistance, following the International League Against Epilepsy guidelines, was slightly stricter than in the original study, we failed to confirm an association between the 24C>T variant in the ABCC2 gene and drug resistance in epilepsy.
Original submitted: 31 May 2011; Revision submitted: 15 August 2011
Papers of special note have been highlighted as: ▪ of interest
References
- 1 Cascorbi I. ABC transporters in drug-refractory epilepsy: limited clinical significance of pharmacogenetics? Clin. Pharmacol. Ther.87,15–18 (2010).
- 2 Loscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia50,1–23 (2009).
- 3 Ufer M, Mosyagin I, Muhle H et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet. Genomics19,353–362 (2009).▪ Suggests an association between pharmacoresistance and the ABCC2 -24C>T polymorphism in Caucasian epileptic patients.
- 4 Ufer M, von Stülpnagel C, Muhle H et al. Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet. Genomics21(10),624–630 (2011).
- 5 Kim DW, Lee SK, Chu K et al. Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. Epilepsy Res.84,86–90 (2009).
- 6 Seo T, Ishitsu T, Oniki K, Abe T, Shuto T, Nakagawa K. ABCC2 haplotype is not associated with drug-resistant epilepsy. J. Pharm. Pharmacol.60,631–635 (2008).
- 7 Kwan P, Wong V, Ng PW et al. Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy. Pharmacogenomics12(3),319–325 (2011).▪ Reveals no association between ABCC2, ABCC5 and ABCG2 polymorphisms and drug resistance in Han Chinese patients with epilepsy.
- 8 Kim WJ, Lee JH, Yi J et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet. Genomics20,249–256 (2010).
- 9 Kwan P, Arzimanoglou A, Berg AT et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia51(6),1069–1077 (2010).
- 10 Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet.81,559–575 (2007).
- 11 Purcell S, Cherny SS, Sham PC. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics19(1),149–150 (2003).
- 12 Nelis M, Esko T, Magi R et al. Genetic structure of Europeans: a view from the North-East. PLoS ONE4,e5472 (2009).
- 13 Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB. Rare variants create synthetic genome-wide associations. PLoS Biol.8,e1000294 (2010).▪ Provides arguments that the association signals in genome-wide association studies caused by multiple rare variants might be mistakingly credited to comman variants.
- 14 Haenisch S, Zimmermann U, Dazert E et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J.7,56–65 (2007).
- 15 Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J.11(1),25–34 (2011).
- 16 Zhang Y, Zhao T, Li W, Vore M. The 5´-untranslated region of multidrug resistance associated protein 2 (MRP2; ABCC2) regulates downstream open reading frame expression through translational regulation. Mol. Pharmacol.77,237–246 (2010).
- 101 Center for Human Genetic Research. PLINK. www.pngu.mgh.harvard.edu/∼purcell/plink/
- 102 Center for Human Genetic Research. Genetic power calculator. www.pngu.mgh.harvard.edu/∼purcell/gpc/cc2.html
